Real-life use of the eutectic mixture lidocaine/prilocaine spray in men with premature ejaculation.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
08
01
2021
accepted:
25
02
2021
revised:
10
02
2021
pubmed:
9
4
2021
medline:
27
4
2022
entrez:
8
4
2021
Statut:
ppublish
Résumé
Topical anaesthetics are considered a first-line therapy option in men with premature ejaculation (PE). A cross-sectional retrospective analysis was performed to evaluate the real-life use of the eutectic mixture of prilocaine/lidocaine spray (FORTACIN™) in a cohort of 198 white-European men who had been consecutively and prospectively seen at a single tertiary-referral andrology centre for self-reported PE and naive for previous PE treatments. Descriptive statistics was used to describe the whole cohort and the paired t-test was applied to investigate potential differences throughout a 12-month follow-up (baseline, 1, 3, 6 and 12 months). Overall, mean (SD) age was 37 (6.5) years. Of all, lifelong, acquired and subjective PE were reported in 101 (51%), 59 (29.8%) and 38 (19.2%) patients at baseline, respectively. FORTACIN™ use increased up to 6 months, with 184 (92.9%) and 128 (66.4%) men who had tried and regularly used the compound, respectively. At 12-month follow-up, 53 (26.8%) men reported a regular use of the compound. Mean Premature Ejaculation Diagnostic Tool score significantly decreased at 6 and 12 months compared to baseline (all p < 0.05). Conversely, mean IELT significantly improved at 6-month follow-up compared to baseline (all p ≤ 0.04). Overall, FORTACIN™ emerged to be a safe and effective treatment option in PE patients of various types, with almost one fourth of patients still under treatment after 12 months. Timing and dosing of the drug can deserve to be adjusted according to patient's needs and their sexual ecology.
Identifiants
pubmed: 33828264
doi: 10.1038/s41443-021-00424-9
pii: 10.1038/s41443-021-00424-9
doi:
Substances chimiques
Lidocaine, Prilocaine Drug Combination
0
Prilocaine
046O35D44R
Lidocaine
98PI200987
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-294Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. EAU guidelines on sexual and reproductive health. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2020.pdf . Assessed 5 April 2020.
McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13:144–52. https://doi.org/10.1016/j.jsxm.2015.12.034 .
doi: 10.1016/j.jsxm.2015.12.034
pubmed: 26953829
Irfan M, Hussain NHN, Noor NM, Mohamed M, Sidi H, Ismail SB. Epidemiology of male sexual dysfunction in Asian and European regions: a systematic review. Am J Mens Health. 2020;14:1557988320937200. https://doi.org/10.1177/1557988320937200 .
doi: 10.1177/1557988320937200
pubmed: 32623948
pmcid: 7338652
Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014;11:1423–41. https://doi.org/10.1111/jsm.12524 .
doi: 10.1111/jsm.12524
pubmed: 24848805
Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II−proposals for DSM-V and ICD-11. J Sex Med. 2006;3:693–705. https://doi.org/10.1111/j.1743-6109.2006.00276.x .
doi: 10.1111/j.1743-6109.2006.00276.x
pubmed: 16839326
Castiglione F, Albersen M, Hedlund P, Gratzke C, Salonia A, Giuliano F. Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. Eur Urol. 2016;69:904–16. https://doi.org/10.1016/j.eururo.2015.12.028 .
doi: 10.1016/j.eururo.2015.12.028
pubmed: 26749092
EMA. FORTACIN
Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103:940–9. https://doi.org/10.1111/j.1464-410X.2009.08456.x .
doi: 10.1111/j.1464-410X.2009.08456.x
pubmed: 19245438
Carson C, Wyllie M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase iii, double-blind, placebo-controlled study. J Sex Med. 2010;7:3179–89. https://doi.org/10.1111/j.1743-6109.2010.01913.x .
doi: 10.1111/j.1743-6109.2010.01913.x
pubmed: 20584124
Porst H, Burri A. Novel treatment for premature ejaculation in the light of currently used therapies: a review. Sex Med Rev. 2019;7:129–40. https://doi.org/10.1016/j.sxmr.2018.05.001 .
doi: 10.1016/j.sxmr.2018.05.001
pubmed: 30057136
Fusco F, Creta M, Mangiapia F, Cirigliano L, Trama F, Pandolfo SD, et al. Perceptions, expectations, preferences, and attitudes toward premature ejaculation, its diagnosis and topical treatment with Fortacin™ spray: results from an expert panel discussion. Res Rep. Urol. 2020;12:211–6. https://doi.org/10.2147/RRU.S250301 .
doi: 10.2147/RRU.S250301
pubmed: 32670915
pmcid: 7337443
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K, et al. Development and validation of a Premature Ejaculation Diagnostic Tool. Eur Urol. 2007;52:565–73. https://doi.org/10.1016/j.eururo.2007.01.028 .
doi: 10.1016/j.eururo.2007.01.028
pubmed: 17275165
Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol. 2007;177:1059–64. https://doi.org/10.1016/j.juro.2006.10.044 . discussion 1064
doi: 10.1016/j.juro.2006.10.044
pubmed: 17296411
Pozzi E, Capogrosso P, Boeri L, Cazzaniga W, Matloob R, Ventimiglia E, et al. Trends in reported male sexual dysfunction over the past decade: an evolving landscape. Int J Impot Res. 2020. https://doi.org/10.1038/s41443-020-0324-7 .
Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816–23. https://doi.org/10.1016/j.eururo.2006.07.004 . discussion 824
doi: 10.1016/j.eururo.2006.07.004
pubmed: 16934919
Georgiadis JR, Simone Reinders AaT, Van der Graaf FHCE, Paans AMJ, Kortekaas R. Brain activation during human male ejaculation revisited. NeuroReport. 2007;18:553–7. https://doi.org/10.1097/WNR.0b013e3280b10bfe .
doi: 10.1097/WNR.0b013e3280b10bfe
pubmed: 17413656
Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92:111–8. https://doi.org/10.1016/s0166-4328(97)00183-6 .
doi: 10.1016/s0166-4328(97)00183-6
pubmed: 9638953
Park HJ, Park NC, Kim TN, Baek SR, Lee KM, Choe S. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study. Sex Med. 2017;5:e99–105. https://doi.org/10.1016/j.esxm.2017.02.003 .
doi: 10.1016/j.esxm.2017.02.003
pubmed: 28395997
pmcid: 5440632
Jenkins LC, Gonzalez J, Tal R, Guhring P, Parker M, Mulhall JP. Compliance with fluoxetine use in men with primary premature ejaculation. J Sex Med. 2019;16:1895–9. https://doi.org/10.1016/j.jsxm.2019.09.017 .
doi: 10.1016/j.jsxm.2019.09.017
pubmed: 31735615
pmcid: 7526797
Salonia A, Rocchini L, Sacca’ A, Pellucchi F, Ferrari M, Carro UD, et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med. 2009;6:2868–77. https://doi.org/10.1111/j.1743-6109.2009.01404.x .
doi: 10.1111/j.1743-6109.2009.01404.x
pubmed: 19656274
Liu H, Zhang M, Huang M, Cai H, Zhang Y, Liu G, et al. Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. Andrologia. 2020;52:e13806 https://doi.org/10.1111/and.13806 .
doi: 10.1111/and.13806
pubmed: 32892379
Ditto KE. SSRI discontinuation syndrome. Awareness as an approach to prevention. Postgrad Med. 2003;114:79–84. https://doi.org/10.3810/pgm.2003.08.1474 .
doi: 10.3810/pgm.2003.08.1474
pubmed: 12926179
Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci JPN. 2000;25:255–61.
pubmed: 10863885
Russo A, Capogrosso P, Ventimiglia E, La Croce G, Boeri L, Montorsi F, et al. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. Int J Clin Pr. 2016;70:723–33. https://doi.org/10.1111/ijcp.12843 .
doi: 10.1111/ijcp.12843
Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a "Waterloo" . Urology. 1AD;82. https://doi.org/10.1016/j.urology.2013.05.018 .
Salonia A, Saccà A, Briganti A, Del Carro U, Dehò F, Zanni G, et al. Quantitative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: a case-controlled study. J Sex Med. 2009;6:1755–62. https://doi.org/10.1111/j.1743-6109.2009.01276.x .
doi: 10.1111/j.1743-6109.2009.01276.x
pubmed: 19453912
Porst H, Burri A. Fortacin
doi: 10.5301/uj.5000275
pubmed: 30047847
pmcid: 6166492
Wyllie MG, Powell JA. The role of local anaesthetics in premature ejaculation. BJU Int. 2012;110:E943–948. https://doi.org/10.1111/j.1464-410X.2012.11323.x .
doi: 10.1111/j.1464-410X.2012.11323.x
pubmed: 22758648
Alghobary M, Gaballah M, El-Kamel MF, State AF, Ismail SR, Selim MK, et al. Oral dapoxetine versus topical lidocaine as on-demand treatment for lifelong premature ejaculation: a randomised controlled trial. Andrologia. 2020;52:e13558 https://doi.org/10.1111/and.13558 .
doi: 10.1111/and.13558
pubmed: 32153050
Symonds T, Perelman M, Althof S, Giuliano F, Martin M, Abraham L, et al. Further evidence of the reliability and validity of the Premature Ejaculation Diagnostic Tool. Int J Impot Res. 2007;19:521–5. https://doi.org/10.1038/sj.ijir.3901567 .
doi: 10.1038/sj.ijir.3901567
pubmed: 17568761